Ajinomoto Bio-Pharma Services is an integrated CDMO with facilities in Belgium, the United States, Japan, and India. Ajinomoto provides comprehensive development, GMP manufacturing, and aseptic fill/finish for small and large molecule APIs and intermediates. The company provides a broad range of platforms and capabilities for preclinical and pilot programs to commercial quantities, including protein expression technologies, oligonucleotide synthesis, antibody–drug conjugates, HPAPIs, biocatalysis, continuous flow manufacturing, and more.